Wegovy Pill Outperforms Shots in Weight Loss
Tap title to read story
A recent real‑world study presented at a medical meeting showed that patients who switched from Novo Nordisk’s Wegovy injections to the daily oral pill continued to lose weight, and in some cases lost more than those who remained on injections. The data, released by the Danish drugmaker, aim to reinforce its position against U.S.
competitor Eli Lilly in the growing market for oral obesity treatments. The study followed a cohort of patients who had previously used the injectable form of the drug and then transitioned to the pill, tracking weight changes over several months.
Results indicated a steady decline in body mass, with average reductions exceeding those observed in the injection group. These findings could influence prescribing habits and insurance coverage decisions, potentially expanding access to the oral formulation for patients seeking a less invasive option.
More context
Timeline
- Study results presented at medical meeting
Why it matters
Immediate US impact: Potential shift in prescribing patterns Possible long-term US impact: Broader insurance coverage for oral weight loss Most affected groups: Patients seeking less invasive weight loss Reader priority: Understanding treatment options
Coverage notes
News is Factual Everywhere
Primary report
Patients who switched from weight-loss injections to Novo Nordisk's daily Wegovy pill continued to lose weight, according to data unveiled at a medical meeting on Wednesday, as the Danish drugmaker seeks to defend its lead over US rival Eli Lilly in the market for oral obesity treatments.
Sources
JQJO Editorial Desk · Human reviewed · AI assisted. Report a correction.
